I will be starting carboplatin/doxirubicin infusions in two weeks for recurrence. I am also going to be getting Keytruda. I would like to hear some of your experiences with this combo as.well as side effects. I am wondering if I will lose my hair again like I did with Taxol. My oncologist said most likely I will along with nausea but I have read that some people have less side effects than with Carbo/Taxol. Thank you so much for your support.
Marietta
Written by
Hockeymom52
To view profiles and participate in discussions please or .
Thank you for your input. No I’m in the U.S. Keytruda is a immunotherapy that has been used for many different cancers. They’re now using it in conjunction with chemotherapy for OC with good results.
Hi Hockeymom52, I'm about to have my second dose of Carbo/Dox for my first full relapse, was on lynparza before for about 1.5 years till stopped working partially and now in the summer more fully stopped working. I'm BRACA 1 High grade serous, just wondering if you are BRCA1 as well? Feeling frustrated why not being offered keytruda here in the UK, I'm mum of 3 aged 49, feeling like I must try get myelf on immunotherapy or drug trial, scared of working my way through chemos that won't be helpful for long....
I feel your frustration. I am Braca negative and was put on Zejula a year ago after my last Chemo only kept my cancer at bay for a few months and stopped working. My oncologist explained to me I was a good candidate for immunotherapy as my tumor burden was greater than 10. That is why I’m on Keytruda. We will see if it works. You might want to discuss this with your oncologist to see if it is an option for you. I think it is available in UK. This is a tough fight we are in but we have to stay strong. Good luck to you 🙏🙏
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.